NICE Expands IMCIVREE Reimbursement Guidance to Adults With BBS
Eligible adults with genetically confirmed Bardet-Biedl syndrome in England, Wales and Northern Ireland can access setmelanotide through the NHS, extending guidance previously limited to patients aged 6 to 17.